Assessing DCog Short for Neurotoxicity in CAR-T

The goal of this pilot study is to determine the effectiveness of DCog Short, a self-reporting, iPad-based application tool, in assessing neurotoxicity in participants undergoing CAR-T cell therapy. This is the first time investigators are examining this tool. The U.S. Food and Drug Administration (FDA) has not approved DCOG Short as a mobile application tool to evaluate neurotoxicity for hematologic malignancies. The research study procedures include screening for eligibility, questionnaires, and cognitive assessments. It is expected that about 40 people will take part in this research study.